Drug interactions
Elranatamab + Riluzole
Severity: Moderate
Elranatamab and Riluzole: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Elranatamab causes cytokine release syndrome, and inflammatory cytokines can temporarily suppress CYP enzymes. Riluzole is mainly metabolised by CYP1A2, so its exposure and adverse effects such as liver enzyme elevation or nausea may rise during and after CRS.
What this interaction means in plain words
Elranatamab and Riluzole can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Elranatamab belongs to Oncology; Riluzole belongs to Miscellaneous.
Why it happens
Cytokine-mediated suppression of CYP1A2 activity during cytokine release syndrome, raising riluzole exposure.
What to do
Monitor for riluzole adverse effects and liver enzymes during step-up dosing and for about 14 days after the first treatment dose, and during and after CRS. Consider dose adjustment or temporary interruption if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elranatamab and Riluzole, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Riluzole
- Fluvoxamine + Riluzole Major
- Cannabidiol + Riluzole Moderate
- Ciprofloxacin + Riluzole Moderate
- Epcoritamab + Riluzole Moderate
- Fexinidazole + Riluzole Moderate
- Givosiran + Riluzole Moderate
Other interactions of Elranatamab
- Elranatamab + Ergotamine Major
- Elranatamab + Pimozide Major
- Bendamustine + Elranatamab Moderate
- Carbamazepine + Elranatamab Moderate
- Clomipramine + Elranatamab Moderate
- Clozapine + Elranatamab Moderate
Frequently asked questions
Can I take Elranatamab with Riluzole?
MediHelp rates the interaction as moderate. Elranatamab and Riluzole can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Elranatamab causes cytokine release syndrome, and inflammatory cytokines can temporarily suppress CYP enzymes. Riluzole is mainly metabolised by CYP1A2, so its exposure and adverse effects such as liver enzyme elevation or nausea may rise during and after CRS.
How serious is the interaction between Elranatamab and Riluzole?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for riluzole adverse effects and liver enzymes during step-up dosing and for about 14 days after the first treatment dose, and during and after CRS. Consider dose adjustment or temporary interruption if toxicity occurs.
What other medicines interact with Riluzole?
MediHelp also lists interactions of Riluzole with, for example, Fluvoxamine, Cannabidiol, Ciprofloxacin. The full list is on the Riluzole page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
